We found that co-transfection with Lv-miR-129 could reverse the Lv-PART1-induced gefitinib resistance (Additional file 3: Figure S3), which further confirmed that miR-129 can enhance anti-cancer drug response in gefitinib resistant ESCC. This evidence concerns the gene PART1 and esophageal squamous cell carcinoma.